First CEO Dismissal in 60 Years! Novo Nordisk Faces Leadership Shakeup Amid Capital Market Pressure, CEO Compensation Far Below Eli Lilly’s

On May 16, 2025, European time, century-old insulin giant Danish company Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will step down. This marks the first time since the 1960s that Novo Nordisk has replaced its CEO in such a drastic manner, highlighting immense pressure from capital markets regarding the company’s performance and stock price.

In its 102-year history, Novo Nordisk has had only five CEOs, all Danish nationals. However, the longstanding management tradition is now challenged by fierce global pharmaceutical market competition. The capital markets have expressed strong dissatisfaction with Novo Nordisk’s recent stock plunge, especially after its blockbuster GLP-1 weight loss drug semaglutide lost its first-mover advantage, causing the stock to drop nearly 60% in the past year.

Since assuming the CEO role in 2017, Fruergaard witnessed the rapid expansion of semaglutide from diabetes treatment to obesity therapy, delivering remarkable growth for Novo Nordisk. Yet, recent stock weakness overshadowed his achievements. According to company disclosures, Fruergaard’s annual salary was approximately 68.2 million Danish kroner (about 9.52 million USD) in 2023, declining to 57.1 million DKK (around 7.97 million USD) in 2024 due to company performance. This is significantly lower than Eli Lilly CEO David Ricks’s 29.2 million USD compensation in 2024.

Industry experts note that US pharmaceutical executives generally receive much higher pay than their European counterparts, with compensation levels and talent mobility heavily influenced by capital market expectations and regional pay cultures. Novo Nordisk’s search for a new CEO likely favors candidates with extensive experience in the US market to counter strong competition from Eli Lilly, although this poses challenges in terms of compensation and cultural integration.

Data shows the top pharmaceutical CEO pay rankings are dominated by US companies. Besides Eli Lilly, Pfizer, Johnson & Johnson, Amgen, Gilead, and Merck all rank high, while European companies are gradually breaking tradition by appointing US nationals as CEOs, such as Novartis and Bayer.

Chinese biopharma firms also increasingly hire US executives, exemplified by BeiGene CEO John Oyler and Zai Lab President Josh Smiley, reflecting a global trend towards international talent. However, the pay gap between these Chinese executives and US pharma giants remains substantial.

Analysts generally agree that appointing a CEO familiar with the US market is key for Novo Nordisk to overcome current challenges and compete globally. As competition in the pharmaceutical sector intensifies, European firms must accelerate commercialization to maintain advantages in innovation and market reach.

Novo Nordisk has confirmed it is actively seeking a new CEO, emphasizing that its US business head David Moore already has deep US market expertise, signaling the company’s focus on strategic adjustment.

A leading cardiovascular expert commented that while Europe has strong R&D and innovation capabilities, it lags behind the US in commercialization speed, resulting in many innovative drugs being dominated globally by US brands. Novo Nordisk’s leadership change is a proactive response to this reality, aiming to bring in a leader with global vision and market experience to drive a new phase of growth and transformation.